CUTX-101 of Fortress Biotech gets US FDA rare pediatric disease designation to treat Menkes disease
Fortress Biotech, an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-stage drugs and drug candidates, announced that... Read More
Case Study: USFDA Pediatric Disease Designation for Imara’s lead Product Candidate IMR-687 for Sickle Cell Disease
Posted on15 May 2017
Comments0
Imara Inc., a biotechnology company dedicated to developing novel therapeutics for patients with sickle cell disease (SCD) and other hemoglobinopathies, announced today... Read More